Abstract: The present invention relates to a nucleic acid molecule, which encodes a polypeptide having alcohol dehydrogenase activity, in particular methanol dehydrogenase activity, comprising having a nucleotide sequence selected from the group consisting of: (i) a nucleotide sequence as set forth in any one of SEQ ID NOs: 1 (mdh2-MGA3), 3 (mdh3-MGA3), or 5 (mdh2-PB1); (ii) a nucleotide sequence having at least 90% sequence identity, more particularly at least 91, 92, 93, 94, 95, 96, 97, 98 or 99% sequence identity, with a nucleotide sequence as set forth in any one of SEQ ID NOs: 1, 3 or 5; (iii) a nucleotide sequence which is degenerate with any one of the nucleotide sequences of SEQ ID NOs: 1, 3 or 5; (iv) a nucleotide sequence which is a part of the nucleotide sequence of any one of SEQ ID NOs: 1, 3 or 5, or of a nucleotide sequence which is degenerate with a sequence of SEQ ID NOs: 1, 3 or 5; (v) a nucleotide sequence encoding all or part of a polypeptide whose amino acid sequence is set forth in any one of SEQ I

Abstract: The present invention relates to medicine, particularly immunology and gastroenterology. Specifically, it relates to probiotic bacteria and extracts thereof for therapeutic use for the treatment of inflammatory disorders such as inflammatory bowel disease. Provided is a composition comprising as active ingredient Faecalibacterium prausnitzii strain HTF-F (DSM 26943) or an extract thereof comprising extracellular polymeric matrix (EPM), and an acceptable carrier, diluent or excipient. Also provided is an anti-inflammatory composition comprising EPM extracted from F. prausnitzii strain HTF-F, and a method for preparing the same.

Abstract: A lower leg prosthesis, for an amputee who has at least one leg having a leg stump, has a distal end and a proximal end. The distal end is connectable to an artificial foot. The proximal end is connectable to the leg stump via a stump socket. A use condition of the lower leg prosthesis includes the distal end being connected to the artificial foot and the proximal end being connected to the leg stump via the stump socket.

Abstract: The present invention relates to the use of an arginase inhibitor for the preparation of a medicament for the prophylactic maintenance therapy of an asthmatic or allergic patient by preventing obstruction of upper and lower airways, in particular allergen-induced bronchial obstruction and/or airway hyperresponsiveness. The patients are either asthmatic or have allergic rhinitis. Preferably, the arginase inhibitor is 2(S)-amino-6-boronohexanoic acid (ABH).

Abstract: The invention relates to novel therapeutic compounds, more in particular to biologically active analogs and uses thereof as medicament, for instance for the treatment of atrial fibrillation. Provided is a compound of the general formula (formula I) wherein R1 is H or a saturated or unsaturated aliphatic moiety comprising 1 to 8 C-atoms; and X is selected from the group consisting of moieties X1, X2, X3, X4, X5 and X6. Exemplary uses include the prevention or therapeutic treatment of a HSF1-mediated disease.

Abstract: The invention relates to the field of medicine. In particular, it relates to recombinant cationic polypeptides and their use as biolubricant. Provided is a biolubricant substance comprising the amino acid sequence[(GKGVP)9]n, wherein n is ?5.

Abstract: A tracheostoma valve (1) comprises a main air passage structure provided with a main valve arrangement. The tracheostoma valve is switchable in response to a spurt of inhalation air from a breathing condition into a speaking condition, while the tracheostoma valve is switchable in response to a spurt of exhalation air from said speaking condition into said breathing condition. The main valve arrangement comprises an at least partly flexible bistable wall portion which has a circumferential bordering edge. At least part of the bordering edge forms a hinging means around which the bistable wall portion is hingeable between a first stable position in which an orifice of the main air passage structure is being blocked, and a second stable position in which said orifice is released.

Abstract: The present invention relates to methods for providing polymeric composites with bone forming, such as with osteogenic and/or osteoinductive and/or osteoconductive, properties. The present invention further relates to polymeric composites provided by the present method and the use of thereof for bone implants, or grafts, specifically the use thereof for orbital floor reconstruction. Specifically, the present invention relates to methods for providing a composite with bone forming properties, the method comprises the steps of: a) providing a liquid, or liquefied, polymeric composition of homopolymers or copolymers of 1,3-trimethylene carbonate (TMC); b) adding to said liquid, or liquefied, polymeric composition one or more agents with osteogenic and/or osteoinductive and/or osteoconductive properties thereby providing a dispersion of said agents in said liquid or liquefied polymeric composition; and c) crosslinking the product obtained, thereby providing a composite with bone forming properties.

Abstract: The invention relates to drug development and synthetic chemistry, in particular to the manufacture of biologically active compounds based on naturally occurring molecules. It also relates to novel biologically active compounds, for example aminoglycoside antibiotics, in a substantially pure regioisomeric form.

Abstract: A lower leg prosthesis, for an amputee who has at least one leg having a leg stump, has a distal end and a proximal end. The distal end is connectable to an artificial foot. The proximal end is connectable to the leg stump via a stump socket. A use condition of the lower leg prosthesis includes the distal end being connected to the artificial foot and the proximal end being connected to the leg stump via the stump socket.

Abstract: The invention provides a use of a substance that is capable of enhancing the amount and/or activity of DnaJB8, or a functional part, derivative and/or analogue thereof, for counteracting protein aggregation.

Abstract: The present invention relates to a photodiode, comprising a photo-active layer which layer comprises at least one electron donating material, and at least one fullerene derivative as an electron accepting material. The present invention further relates to a method for making such a photo diode, to a photo-active layer and to a fullerene derivative.

Abstract: A tracheostoma valve (1) comprises a main air passage structure provided with a main valve arrangement. The tracheostoma valve is switchable in response to a spurt of inhalation air from a breathing condition into a speaking condition, while the tracheostoma valve is switchable in response to a spurt of exhalation air from said speaking condition into said breathing condition. The main valve arrangement comprises an at least partly flexible bistable wall portion which has a circumferential bordering edge. At least part of the bordering edge forms a hinging means around which the bistable wall portion is hingeable between a first stable position in which an orifice of the main air passage structure is being blocked, and a second stable position in which said orifice is released.

Abstract: A pharmaceutical composition for the treatment of a disease caused by a bacterium that belongs to the group of nocardioform actinomycetes, said composition comprising an effective amount of a compound selected from compound I, (+)-compound II, (?)-compound II, compound III, or mixtures thereof.

Abstract: Described is a modulatable injection barrier and a semiconductor element comprising same. More particularly, the invention relates to a two-terminal, non-volatile programmable resistor. Such a resistor can be applied in non-volatile memory devices, and as an active switch e.g. in displays. The device comprises, in between electrode layers, a storage layer comprising a blend of a ferro-electric material and a semiconductor material. Preferably both materials in the blend are polymers.

Abstract: The present invention relates to the field of preventive and therapeutic medicine, in particular to peptide formulations. Provided is a pH-buffered aqueous formulation comprising oxytocin, vasopressin or an analogue thereof and at least one non-toxic source of divalent metal ions in a concentration of at least 2 mM, and the use of the formulation for the manufacture of a medicament for therapeutic and/or prophylactic treatments. Also provided is a method for treating or preventing haemorrhage in a subject in need thereof, comprising administering to said subject an effective dosage amount of an oxytocin formulation according to the invention. Further provided is a method for treating or preventing diabetes insipidus or vasodilatory shock in a subject in need thereof, comprising administering to said subject an effective dosage amount of a vasopressin formulation according to the invention.

Abstract: The present invention relates to novel cytokines, which have a modified selectivity/specificity for their cognate receptors. In particular, the invention relates to a variant TRAIL protein, which has superior selectivity for the death receptor 4 (TRAIL-RI) over the death receptor 5 (TRAIL-R2). In addition, the invention relates to a variant TRAIL protein which exhibits superior selectivity for the death receptor 4 (TRAIL-R1) over the decoy receptors DcR1 (TRAIL-R3) and DcR2 (TRAIL-R4).

Abstract: The present invention relates to the use of a mutant TRAIL protein to treat various cancers in mammals. The invention provides a variant TRAIL protein, which has superior selectivity for the death receptor 5, for treating a mammal diagnosed with cancer.

Abstract: The present invention relates to a photodiode including a photo-active layer, which layer includes at least one electron donating material, and at least one fullerene derivative as an electron accepting material. The present invention further relates to a method for making such a photodiode, to a photo-active layer and to a fullerene derivative.

Abstract: The invention provides means and methods for efficiently cloning nucleic acid sequences of interest in micro-organisms that are less amenable to conventional nucleic acid manipulations, as compared to, for instance, E.coli. The present invention enables high-throughput cloning (and, preferably, expressing) of a nucleic acid of interest in a first kind of micro-organism, while an initial (preferably high throughput) cloning of the nucleic acid of interest is done in a second kind of micro-organism.